FDA Eyes Adverse Events For Mylan's Wixela Inhub

Assessing Need For Additional Reminders About Differences To Advair

As patients log device complaints for Mylan’s Advair Diskus generic Wixela Inhub, the agency is assessing whether additional reminders about the products’ differences are needed.

Survelliance camera
The FDA's Office of Generic Drugs does not want differences between complex generics and their reference products to hinder uptake • Source: Shutterstock

More from Regulation

More from Policy & Regulation